Diagnosis and Treatment of TRK Fusion-Positive Lung Cancer
Diagnosis and Treatment of TRK Fusion-Positive Lung Cancer
How will your clinical decisions impact a patient at two key stages in their journey?
How will your clinical decisions impact a patient at two key stages in their journey?
Prof. Fernando López-Ríos, Prof. Mark Socinski
In this interactive patient case study developed by independent experts, you'll meet a patient with TRK fusion-positive lung cancer at initial diagnosis and then again at disease progression two years later.
As you learn about the potential clinical management and treatment options, you'll get the chance to make clinical decisions and see how they impact the patient's trajectory.
Prof. Fernando López-Ríos
Pathologist
12 de Octubre University Hospital, Madrid
Spain
Prof. Mark Socinski
Medical Oncologist
Advent Health Cancer Institute, Orlando, Florida
United States (US)
Diagnosis and Treatment of TRK Fusion-Positive Lung Cancer: Interactive patient case study
Interactive patient case | 
60 min
|
May 2023
I agree that this educational programme:
Clinical Takeaways
-
Next generation sequencing is the main testing method to identify NTRK fusions. If immunohistochemistry is used as a screening method, all positive findings need to be confirmed with next generation sequencing
-
Based on robust efficacy data, larotrectinib and entrectinib are two approved first-generation TRK inhibitors. Dosing recommendations should be followed to manage the known adverse events
-
First-generation TRK inhibitors may lead to acquired mechanisms of resistance: 1) on-target: through the development of NTRK gene mutations or 2) off-target: through the other genomic alterations, including BRAFp. V6OOE mutation, KRASp. G12D mutation, and MET amplification
Coming soon
You'll soon be able to take this programme from your smartphone. In the meantime, please enjoy from your desktop or tablet.
This educational programme is supported by an Independent Medical Education Grant from Bayer
PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.
Other programmes of interest
73 min
Other programmes developed by Prof. Fernando López-Ríos
Prof. Fernando López-Ríos
Pathologist
12 de Octubre University Hospital, Madrid
Spain
